Clinical Cancer Research · 2006 · 160 citations · 39 references
PHA-680632 is the first representative of a new class of Aurora inhibitors with a high potential for further development as an anticancer therapeutic. On treatment, different cell lines respond differentially, suggesting the absence of critical cell cycle checkpoints that could be the basis for a favorable therapeutic window.
39
Elizabeth A. Harrington, David Bebbington, Jeffrey R. Moore et al. · Nature Medicine · 2004 · 948 citations · Full text
Selective Small-molecule Inhibitor, Signal Transduction, Signaling Pathway +11